Wealth Alliance Advisory Group LLC Purchases 813 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Wealth Alliance Advisory Group LLC lifted its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 73.8% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,915 shares of the medical research company's stock after acquiring an additional 813 shares during the quarter. Wealth Alliance Advisory Group LLC's holdings in Thermo Fisher Scientific were worth $953,000 at the end of the most recent quarter.

Other hedge funds also recently made changes to their positions in the company. Bernard Wealth Management Corp. purchased a new position in Thermo Fisher Scientific during the fourth quarter valued at approximately $25,000. Barrett & Company Inc. bought a new stake in Thermo Fisher Scientific during the 4th quarter valued at $28,000. FPC Investment Advisory Inc. purchased a new position in Thermo Fisher Scientific during the 4th quarter valued at about $28,000. Pillar Financial Advisors LLC bought a new position in shares of Thermo Fisher Scientific during the fourth quarter valued at approximately $29,000. Finally, Ameriflex Group Inc. bought a new stake in shares of Thermo Fisher Scientific during the 4th quarter valued at about $30,000. 89.23% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

TMO has been the subject of a number of recent research reports. Scotiabank lowered their price target on shares of Thermo Fisher Scientific from $650.00 to $605.00 and set a "sector perform" rating for the company in a research report on Friday, April 25th. Citigroup decreased their target price on shares of Thermo Fisher Scientific from $650.00 to $570.00 and set a "neutral" rating for the company in a research note on Tuesday, March 4th. Robert W. Baird cut their target price on shares of Thermo Fisher Scientific from $603.00 to $573.00 and set an "outperform" rating for the company in a research report on Thursday, April 24th. The Goldman Sachs Group set a $610.00 price objective on Thermo Fisher Scientific and gave the company a "buy" rating in a research report on Wednesday, April 23rd. Finally, Royal Bank of Canada decreased their price target on Thermo Fisher Scientific from $651.00 to $637.00 and set an "outperform" rating on the stock in a report on Thursday, April 24th. Four equities research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the stock. According to data from MarketBeat, Thermo Fisher Scientific presently has an average rating of "Moderate Buy" and a consensus price target of $605.30.

Insider Buying and Selling

In other Thermo Fisher Scientific news, SVP Michael A. Boxer sold 3,775 shares of Thermo Fisher Scientific stock in a transaction on Monday, March 10th. The shares were sold at an average price of $532.52, for a total transaction of $2,010,263.00. Following the completion of the sale, the senior vice president now owns 10,816 shares of the company's stock, valued at approximately $5,759,736.32. The trade was a 25.87% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Gianluca Pettiti sold 300 shares of the stock in a transaction dated Monday, April 28th. The shares were sold at an average price of $429.93, for a total value of $128,979.00. Following the completion of the transaction, the executive vice president now directly owns 23,167 shares in the company, valued at $9,960,188.31. The trade was a 1.28% decrease in their position. The disclosure for this sale can be found here. 0.33% of the stock is owned by corporate insiders.

Thermo Fisher Scientific Trading Down 1.4%

Shares of TMO stock traded down $5.78 during trading hours on Thursday, reaching $397.88. 2,502,299 shares of the stock traded hands, compared to its average volume of 1,898,316. The business has a fifty day moving average price of $424.35 and a 200 day moving average price of $497.38. The company has a quick ratio of 1.29, a current ratio of 1.66 and a debt-to-equity ratio of 0.59. Thermo Fisher Scientific Inc. has a 1-year low of $390.50 and a 1-year high of $627.88. The firm has a market capitalization of $150.20 billion, a PE ratio of 24.07, a PEG ratio of 2.99 and a beta of 0.82.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last issued its quarterly earnings data on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $5.10 by $0.05. Thermo Fisher Scientific had a net margin of 14.78% and a return on equity of 17.51%. The firm had revenue of $10.36 billion during the quarter, compared to analysts' expectations of $10.23 billion. During the same period in the prior year, the company posted $5.11 earnings per share. Thermo Fisher Scientific's revenue for the quarter was up .2% on a year-over-year basis. On average, equities research analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, July 15th. Investors of record on Friday, June 13th will be given a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.43%. The ex-dividend date of this dividend is Friday, June 13th. Thermo Fisher Scientific's dividend payout ratio (DPR) is currently 10.09%.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.